Tercica, Inc.

U.K. high court rules on patent litigation regarding growth hormone drug

Published in Drug Law Weekly, June 28th, 2005

Tercica, Inc. (TRCA) announced that the High Court of Justice (Chancery Division Patent Court) in London, England, issued rulings in the patent infringement litigation case of Tercica, Inc. versus Insmed Inc. and Avecia Limited, and in the related patent revocation action of Insmed Inc. and Avecia Limited versus Genentech, Inc.

Insmed and Avecia had made motions for summary judgment in each matter. Their motions attacked the validity of the Tercica/Genentech patent at issue. The court ruled in Tercica's and Genentech's favor in denying both motions. The court also ordered Insmed and Avecia to pay Tercica's and Genentech's legal fees.

Tercica's suit...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry